Press release
Propulsion of Aplastic Anemia Clinical Trial Pipeline as Novel and Extensive 8+ Therapies Likely to Enter in the Domain | DelveInsight
Aplastic Anemia Pipeline
In the Aplastic Anemia Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Aplastic Anemia NDA approvals (if any), and product development activities comprising the technology, Aplastic Anemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Aplastic Anemia Pipeline treatment landscape of the report, click here @ Aplastic Anemia Pipeline Outlook- https://www.delveinsight.com/report-store/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Aplastic Anemia Pipeline Report
• DelveInsight's Aplastic Anemia Pipeline analysis depicts a robust space with 8+ active players working to develop 8+ pipeline treatment therapies.
• The leading companies working in the Aplastic Anemia Market include Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others.
• Promising Aplastic Anemia Pipeline Therapies in the various stages of development include PF-06462700, Romiplostim, Eltrombopag 25 mg, Eltrombopag, Eltrombopag, Cyclosporine, AMG531, Hetrombopag Olamine+Standard Therapy, Hetrombopag Olamine, and others.
• On June 2023, Novartis Pharmaceuticals announced a study of phase 2 clinical trials for Eltrombopag 25 mg. This is a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA). Treatment with eltrombopag will be started at 25 mg/day and increased by 25 mg/day every 2 weeks according to the platelet count up to 150 mg/day. The hematological response rate will be assessed at 3, 6 months and 1 year after starting the study treatment (Week 13, 26 and 52).
• On July 2023, Regeneron Pharmaceuticals announced a study of phase 1 & 2 clinical trials for REGN7257. The primary objective of this study is to assess the safety and tolerability of REGN7257 in patients with immunosuppressive therapy (IST)-refractory or IST-relapsed severe aplastic anemia (SAA). An additional primary objective (for Part B only) is to evaluate the clinical efficacy of REGN7257 in patients with IST-refractory or IST-relapsed SAA.
Aplastic Anemia Overview
Aplastic anemia is a medical condition that damages stem cells in a person's bone marrow. These cells are responsible for making red blood cells, white blood cells, and platelets, which are vital to human health. A rare and serious condition, aplastic anemia can develop at any age.
For further information, refer to the detailed Aplastic Anemia Unmet Needs, click here for Aplastic Anemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Aplastic Anemia Emerging Drugs Profile
• PF-06462700: Pfizer
• REGN7257: Regeneron Pharmaceuticals
• BL-8040: BioLineRx, Ltd.
Aplastic Anemia Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the Aplastic Anemia. The companies which have their Aplastic Anemia drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.
Request a sample and discover the recent advances in Aplastic Anemia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Aplastic Anemia Segmentation- https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Aplastic Anemia Drugs and Companies
• PF-06462700: Pfizer
• Romiplostim: Kyowa Kirin Co. Ltd.
• Eltrombopag 25 mg: Novartis Pharmaceuticals
Aplastic Anemia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Aplastic Anemia Therapeutics Market include-
Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others.
Dive deep into rich insights for drugs for Aplastic Anemia Pipeline, click here @ Aplastic Anemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Aplastic Anemia Pipeline Report
• Coverage- Global
• Companies- Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and others.
• Therapies- PF-06462700, Romiplostim, Eltrombopag 25 mg, Eltrombopag, Eltrombopag, Cyclosporine, AMG531, Hetrombopag Olamine+Standard Therapy, Hetrombopag Olamine, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Dive deep into rich insights for drugs for Aplastic Anemia Pipeline, click here @ Aplastic Anemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Aplastic Anemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Aplastic Anemia- DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Aplastic Anemia Collaboration Deals
9. Late Stage Products (Phase III)
10. PF-06462700: Pfizer
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. BL-8040: BioLineRx, Ltd.
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I/II)
16. REGN7257: Regeneron Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Aplastic Anemia Key Companies
20. Aplastic Anemia Key Products
21. Aplastic Anemia- Unmet Needs
22. Aplastic Anemia- Market Drivers and Barriers
23. Aplastic Anemia- Future Perspectives and Conclusion
24. Aplastic Anemia Analyst Views
25. Aplastic Anemia Key Companies
26. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Propulsion of Aplastic Anemia Clinical Trial Pipeline as Novel and Extensive 8+ Therapies Likely to Enter in the Domain | DelveInsight here
News-ID: 3184111 • Views: …
More Releases from DelveInsight Business Research
Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape: DelveInsight …
A comprehensive deep dive into one of oncology's fastest-expanding therapeutic classes covering pipelines, clinical advancements, strategic collaborations, and future-market perspectives
DelveInsight, a prominent market research and strategic consulting company specializing in the life sciences industry, has unveiled its latest intelligence offering, "Antibody-Drug Conjugates (ADCs) - Competitive Landscape, 2025." This extensive report provides a panoramic view of the global ADC space, including detailed evaluations of more than 200 biopharmaceutical companies and 220+…
Atopic Dermatitis Pipeline 2025: FDA Approvals and Clinical Trials Landscape wit …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Ankylosing Spondylitis Pipeline 2025: Therapies, MOA Insights, and Key Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Diabetic Foot Ulcers Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Foot Ulcers pipeline constitutes 20+ key companies continuously working towards developing 25+ Diabetic Foot Ulcers treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…
More Releases for Aplastic
Acquired Aplastic Anemia Market: Growth Trends to Watch
Acquired Aplastic Anemia Market valued at USD X.X Billion in 2024 and is projected to reach USD X.X Billion by 2032, growing at a CAGR of X.X% from 2025 to 2032.
What is the Acquired Aplastic Anemia Market and Why is It Significant?
The Acquired Aplastic Anemia market refers to the segment of healthcare focused on diagnosing, treating, and managing acquired aplastic anemia, a rare blood disorder where the bone marrow fails…
Strategic Partnerships Drive Advancements In Aplastic Anemia Treatment And Resea …
How Are the key drivers contributing to the expansion of the aplastic anemia market?
The escalating expenses on healthcare are anticipated to stimulate the aplastic anemia market's expansion in the future. This growth in healthcare spending is mainly attributed to factors like aging populations and rising chronic illnesses that necessitate expensive treatments. Investments in healthcare facilitate treatments for aplastic anemia by providing funds for specialized medical institutions, innovative therapies, and research…
Leading Element Driving Change in the Aplastic Anemia Market in 2025: Impact Of …
What Is the Estimated Market Size and Growth Rate for the Aplastic Anemia Market?
The market size of aplastic anemia has seen considerable growth in past years. There is expected growth from $6.63 billion in 2024 to $7.03 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The historic growth of this market can be credited to several factors, including a rise in the incidence of blood disorders,…
Aplastic Anemia Market: A Growing Need for Treatment
The aplastic anemia market has witnessed significant growth in recent years, driven by advancements in medical technology, increasing awareness of the condition, and the desire for effective treatment options. This post will delve into the market, exploring its size, share, opportunities, challenges, demand, and trends.
Market Size and Share
The aplastic anemia market is a substantial segment of the global hematology and oncology industry. While precise figures can vary depending on data…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Global Acquired Aplastic Anemia Market Insights, Forecast
Acquired aplastic anemia is a rare, serious blood disorder, due to failure of the bone marrow failure to produce blood cells. Bone marrow is the spongy substance found in the center of the bones of the body, in adults mainly the spine, pelvis, and large bones of the legs. The global Acquired Aplastic Anemia market is valued at xx million US$ in 2018 and will reach xx million US$ by…
